These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 39350781

  • 1. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR, Martins C, Teixeira M, Tomás D.
    World J Gastroenterol; 2024 Sep 14; 30(34):3929-3931. PubMed ID: 39350781
    [Abstract] [Full Text] [Related]

  • 2. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V.
    Cochrane Database Syst Rev; 2020 Jan 27; 1(1):CD012381. PubMed ID: 31984480
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.
    N Engl J Med; 2017 May 04; 376(18):1723-1736. PubMed ID: 28467869
    [Abstract] [Full Text] [Related]

  • 8. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun 04; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panés J.
    Inflamm Bowel Dis; 2021 May 17; 27(6):816-825. PubMed ID: 32766762
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, Guo X, Wu J, Vranic I, Panaccione R, Vermeire S.
    United European Gastroenterol J; 2024 Jul 17; 12(6):793-801. PubMed ID: 38778549
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C, Harness J, Tan H, Menter A.
    J Eur Acad Dermatol Venereol; 2014 Feb 17; 28(2):192-203. PubMed ID: 23294276
    [Abstract] [Full Text] [Related]

  • 20. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S.
    World J Gastroenterol; 2024 Apr 07; 30(13):1871-1886. PubMed ID: 38659488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.